233 related articles for article (PubMed ID: 33271325)
1. Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
Imano H; Kato R; Ijiri Y; Hayashi T
Toxicol In Vitro; 2021 Mar; 71():105063. PubMed ID: 33271325
[TBL] [Abstract][Full Text] [Related]
2. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
[TBL] [Abstract][Full Text] [Related]
3. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
4. Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction.
Kato R; Ijiri Y; Hayashi T; Uetrecht J
J Toxicol Sci; 2020; 45(11):673-680. PubMed ID: 33132241
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract][Full Text] [Related]
8. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
[TBL] [Abstract][Full Text] [Related]
9. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Bhargava P; Robinson MO
Curr Oncol Rep; 2011 Apr; 13(2):103-11. PubMed ID: 21318618
[TBL] [Abstract][Full Text] [Related]
10. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
Chen YC; Chen JH; Hsieh FI
J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
Massey PR; Okman JS; Wilkerson J; Cowen EW
Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
13. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
14. [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Bretagne M; Boudou-Rouquette P; Huillard O; Thomas-Schoemann A; Chahwakilian A; Orvoen G; Arrondeau J; Tlemsani C; Cessot A; Cabanes L; Blanchet B; Coriat R; Alexandre J; Goldwasser F
Bull Cancer; 2016 Mar; 103(3):259-72. PubMed ID: 26832420
[TBL] [Abstract][Full Text] [Related]
15. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Török S; Döme B
Magy Onkol; 2012 Mar; 56(1):3-15. PubMed ID: 22403757
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib and reactive metabolite of sunitinib activate inflammasomes: Implications for multi tyrosine kinase inhibitor-Iiduced immune related adverse events.
Kato R; Ijiri Y
Pharmazie; 2022 Feb; 77(2):54-58. PubMed ID: 35209964
[TBL] [Abstract][Full Text] [Related]
17. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
León-Mateos L; Mosquera J; Antón Aparicio L
Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
Kumar R; Knick VB; Rudolph SK; Johnson JH; Crosby RM; Crouthamel MC; Hopper TM; Miller CG; Harrington LE; Onori JA; Mullin RJ; Gilmer TM; Truesdale AT; Epperly AH; Boloor A; Stafford JA; Luttrell DK; Cheung M
Mol Cancer Ther; 2007 Jul; 6(7):2012-21. PubMed ID: 17620431
[TBL] [Abstract][Full Text] [Related]
20. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Verzoni E; Grassi P; Montone R; Galli G; Necchi A; Procopio G
Tumori; 2015; 101(6):701-3. PubMed ID: 26108242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
